Patents by Inventor Paul José Pierre Marie Maes

Paul José Pierre Marie Maes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
    Patent number: 10668084
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: June 2, 2020
    Assignee: Acerus Biopharma Inc.
    Inventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
    Patent number: 10111888
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: October 30, 2018
    Assignee: ACERUS BIOPHARMA INC.
    Inventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • INTRANASAL 0.15% AND 0.24% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER
    Publication number: 20160271144
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Application
    Filed: October 23, 2015
    Publication date: September 22, 2016
    Inventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • INTRANASAL 0.45% AND 0.48% TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER
    Publication number: 20160250228
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Application
    Filed: October 23, 2015
    Publication date: September 1, 2016
    Inventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER
    Publication number: 20160175321
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Application
    Filed: October 20, 2015
    Publication date: June 23, 2016
    Inventors: Wayne Carper, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS
    Publication number: 20160113946
    Abstract: The present invention relates to testosterone topical formulations, especially high testosterone concentration formulations, such as between about 6% to about 15% w/w or higher, for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing undesired testosterone spike in blood levels or testosterone transference, following topical administration. The testosterone topical formulations of the present invention are safe, convenient to use, well tolerated, stable and easily and reproducibly manufactured on scale up. Moreover, because supra-normal and sub-normal testosterone blood levels are believed to be essentially kept to a minimum or avoided and the testosterone serum levels are believed to remain essentially constant during dose life, i.e.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 28, 2016
    Inventors: Werner Oberegger, Paul José Pierre Marie Maes
  • CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS
    Publication number: 20150297733
    Abstract: The present invention relates to testosterone topical formulations, especially high testosterone concentration formulations, such as between about 6% to about 15% w/w or higher, for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing undesired testosterone spike in blood levels or testosterone transference, following topical administration.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 22, 2015
    Inventors: Werner Oberegger, Paul José Pierre Marie Maes
  • MALE TESTOSTERONE TITRATION METHODS, MALE INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING HYPOGONADISM AND TRT
    Publication number: 20150290217
    Abstract: The present invention relates to pernasal testosterone bio-adhesive gel formulations for intranasal administration and testosterone replacement treatment methods for using the pernasal testosterone bio-adhesive gel formulations for providing sustained intranasal delivery of testosterone to testosterone deficient males to treat, for example, male subjects diagnosed with hypogonadism. The present invention is also concerned with a novel titration method to determine the appropriate daily treatment regimen, i.e., a BID or TID treatment regimen, to administer the intranasal gels of the present invention to treat hypogonadism or TRT.
    Type: Application
    Filed: November 21, 2013
    Publication date: October 15, 2015
    Inventors: Wayne Kreppner, Paul José Pierre Marie Maes